Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Employees - 54, CEO - Dr. Benjamin J. Zeskind M.B.A., Ph.D., Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -5.79, Piotroski Score(max is 10): 3, Working Capital: $33098000, Total Assets: $50681000, Retained Earnings: $-239341000, EBIT: -64230507, Total Liabilities: $8838000, Revenue: $0

AryaFin Target Price - $1.06 - Current Price $ - Analyst Target Price $